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Abstract
Mesenchymal stem/stromal cells (MSCs) obtained from pluripotent stem cells (PSCs) constitute an interesting
alternative to classical MSCs in regenerative medicine. Among their many mechanisms of action, MSC extracellular
vesicles (EVs) are a potential suitable substitute for MSCs in future cell-free-based therapeutic approaches. Unlike cells,
EVs do not elicit acute immune rejection, and they can be produced in large quantities and stored until ready to use.
Although the therapeutic potential of MSC EVs has already been proven, a thorough characterization of MSC EVs is
lacking. In this work, we used a label-free liquid chromatography tandem mass spectrometry proteomic approach to
identify the most abundant proteins in EVs that are secreted from MSCs derived from PSCs (PD-MSCs) and from their
parental induced PSCs (iPSCs). Next, we compared both datasets and found that while iPSC EVs enclose proteins that
modulate RNA and microRNA stability and protein sorting, PD-MSC EVs are rich in proteins that organize extracellular
matrix, regulate locomotion, and influence cell–substrate adhesion. Moreover, compared to their respective cells, iPSCs
and iPSC EVs share a greater proportion of proteins, while the PD-MSC proteome appears to be more specific.
Correlation and principal component analysis consistently aggregate iPSCs and iPSC EVs but segregate PD-MSC and
their EVs. Altogether, these findings suggest that during differentiation, compared with their parental iPSC EVs, PD-
MSC EVs acquire a more specific set of proteins; arguably, this difference might confer their therapeutic properties.
Introduction
Mesenchymal stem/stromal cells (MSCs) are one of the
most promising cell types in regenerative medicine.
Because of their multilineage differentiation potential1
and immunological modulatory properties2–5, MSCs are
currently being tested in more than 6900 clinical studies
(www.clinicaltrials.gov, query: Mesenchymal stem cells
OR Mesenchymal Stromal Cells OR MSCs, searched on
December 2017). Initially, MSCs were believed to be
recruited at the site of injury; however, it was later pro-
posed that their therapeutic action was directly exerted
via replacing the damaged tissue. Currently, in addition to
direct differentiation, MSCs are believed to secrete a
myriad of soluble factors and extracellular vesicles (EVs)
that modulate the behavior of cells in a paracrine fash-
ion6–9.
MSCs can be readily isolated from adult tissues such as
the bone marrow, adipose tissue, and umbilical cord.
However, MSC therapeutic properties decline rapidly
in vitro with the number of passages10,11. This poses a
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substantial problem when expanding cells to obtain the
amount required for clinical purposes. Recently, MSCs
were obtained from pluripotent stem cells (PSCs)12–14.
PSCs are mainly found in the inner cell mass from the
blastocyst, called embryonic stem cells (ESCs); adult cells
reprogrammed by forced expression of pluripotency
transcription factors are called induced PSCs (iPSCs)15.
PSCs are able to differentiate into endoderm, ectoderm,
and mesoderm lineage, including MSCs. MSCs derived
from PSCs (PD-MSCs) can differentiate into the osteo-
genic, chondrogenic, and adipogenic lineage; have surface
markers such as CD90, CD73, and CD105; and have
immunological modulatory properties that make them
indistinguishable from patient-derived MSCs16.
The therapeutic properties of MSCs are explained, at
least in part, by the paracrine action of EVs. EVs are
classified mainly by their size and cargo17,18. These
include apoptosomes, microvesicles, and the smaller
exosomes. EVs are particularly important in explaining
MSC regenerative features8,19–21, and since they mediate
intercellular communication, they are considered key
components of a potential cell-free, off-the-shelf therapy.
MSC EVs are already being clinically tested for graft-
versus-host disease and chronic kidney disease22. Addi-
tionally, PD-MSC EVs were found to protect against renal
ischemia/reperfusion injury23, and they have multiple
effects on cutaneous wound healing, bone regeneration,
and hindlimb ischemia and vascular injury repair24.
EVs usually enclose lipids, mRNA, microRNAs (miR-
NAs), and proteins that upon recognition of their target
cells are able to regulate their function. While micro-
vesicles originate directly from shedding of the plasma
membrane, exosomes are formed by invagination of a
specific endosomal compartment called multivesicular
bodies (MVBs). Exosomes are then released upon fusion
of MVBs to the plasma membrane, and they either adhere
to the membrane of target cells or are internalized by the
latter, which induces specific signals25. Loading of cargo
into exosomes is far from being a stochastic event. In
particular, proteins can be directed to exosomes through
endosomal sorting complexes required for transport
(ESCRT)-dependent or ESCRT-independent mechanisms,
where tetraspanins and the lipid composition of vesicles
plays key roles26–30. In addition, ESCRT is also involved in
the sorting of proteins to shedding vesicles such as
microvesicles31.
Although there is an increasing amount of literature
regarding the viability of PD-MSCs as a robust source of
MSCs, little is known regarding the content of their
secretome. In particular, in this work, we sought to gain
insight regarding the proteomic content of their EVs and
aimed to further characterize them with the objective of
improving the chances of their future application in cell-
free-based therapy.
Materials and methods
Cell culture
WA09 human embryonic stem cells were purchased
from WiCell (Madison, WI, USA). iPSCs were generated
in our laboratory as previously described32. Briefly, fore-
skin fibroblasts were reprogrammed by transfection with
the STMCCA lentivirus, which was generously obtained
from Gustavo Mostoslavsky33. Several clones have been
characterized in our laboratory via demonstration of their
pluripotent state, its ability to differentiate into cells from
the three germinal layers, and the formation of teratomas.
For this paper, we have used the clone FN2.1. PSCs were
cultured in E8-defined medium over vitronectin-coated
plates. PD-MSCs were differentiated in our laboratory as
previously published16. Briefly, on day 0 of differentiation,
PSCs were incubated with Accutase until the cells were
completely dissociated, and they were plated onto Geltrex-
coated plates and suspended in α-minimum essential
medium (α-MEM) supplemented with platelet lysate 10%
and B27 1/100 (all from Life Technologies, Carlsbad, CA,
USA). A ROCK inhibitor (Y27632 10 ng/ml; Tocris, Avon,
Bristol, UK) was added every time the cells were passaged
until day 14 of differentiation. From that day onwards, the
cells were passed on plastic dishes with no coating and
were grown in medium supplemented with PL 10% and
penicillin–streptomycin. Wharton jelly (WJ)-MSCs were
grown in α-MEM supplemented with PL 10%. All
experiments were performed using MSCs maintained in
culture until passage ten or less.
EV isolation and transmission electron microscopy
EVs were isolated according to Théry et al. 34. Briefly,
cells were seeded to reach 80% of confluence. The cells
were then cultured for 24 h in E8-defined medium (Life
Technologies). The cell culture supernatants were then
centrifuged at 4 °C, 2000 x g for 10min, which was fol-
lowed by another centrifugation at 4 °C, 10,000 x g for 30
min and one last ultracentrifugation at 4 °C, 100,000 x g for
90min. The EVs were the washed and ultracentrifuged
again. The pellet was then resuspended in phosphate-
buffered saline (PBS) or RIPA Buffer (Sigma-Aldrich, St.
Louis, MO, USA) without protease inhibitors and was
stored at −80 °C, depending on the experiment to be
performed. The resuspended EVs were quantified via the
Pierce BCA Protein Assay (Thermo Scientific, Waltham,
MA, USA). Transmission electron microscopy (TEM) was
performed according to Théry et al.34 by the LANAIS-MIE
Core Facility at the IBCN Institute, University of Buenos
Aires/CONICET (National Research Council) using a
Zeiss EM 109T with a Gatan ES1000W digital camera.
Flow cytometry analysis
Flow cytometry analyses were performed in a BD Accuri
cytometer. First, 20 µg of EV resuspension was bound to
La Greca et al. Experimental & Molecular Medicine (2018) 50:119 Page 2 of 12
Official journal of the Korean Society for Biochemistry and Molecular Biology
20 µl of anti-CD63 antibody-coated magnetic beads (Life
Technologies), as recommended by the manufacturer.
Next, a second staining with anti-CD81-PE-conjugated
antibody or anti-CD9-APC-conjugated antibody (Mole-
cular Probes, Life Technologies, Eugene, OR, USA) was
performed for 30min at room temperature. The beads
were then washed with PBD plus albumin 0.1% and were
analyzed. At least 5000 events per treatment were
counted.
Mass spectrometry analysis
Liquid chromatography tandem mass spectrometry
(LC-MS/MS) was performed on three biological replicates
of each type of EVs and one biological replicate of each
type of cell. The datasets were then grouped according to
the EV or cell type. Each group was run at least three
times. Protein digestion and mass spectrometry analysis
were performed at the Proteomics Core Facility CEQUI-
BIEM, at the University of Buenos Aires/CONICET
(National Research Council) as follows: the protein sam-
ples were reduced with dithiothreitol in 50 mM of
ammonium bicarbonate at a final concentration of 10 mM
(45min, 56 °C) and were alkylated with iodoacetamide
in the same solvent at a final concentration of 20 mM
(40min, room temperature (RT), in darkness). This pro-
tein solution was precipitated with 1/5 volumes of tri-
chloroacetic acid at −20 °C for at least 2 h and was
centrifuged at maximum speed for 10 min (4 °C). The
pellet was washed twice with cool acetone and was dried
at RT. The proteins were resuspended in ammonium
bicarbonate 50mM, pH= 8, and were digested using
trypsin (V5111; Promega, Madison, WI, USA). Next, the
peptides were purified and desalted via ZipTip C18 col-
umns (Millipore, Burlington, MA, USA).
The digests were analyzed via nanoLC-MS/MS in a
Thermo Scientific Q-Exactive Mass Spectrometer coupled
to a nanoHPLC EASY-nLC 1000 (Thermo Scientific). For
the LC-MS/MS analysis, approximately 1 μg of peptides
was loaded onto the column and was eluted for 120 min
using a reversed-phase column (C18, 2 µm, 100 A, 50 µm
x 150mm) Easy-Spray Column PepMap RSLC (P/N
ES801) that was suitable for separating protein complexes
with a high degree of resolution. The flow rate used for
the nanocolumn was 300 nl min−1, and the solvent range
used was from 7% B (5 min) to 35% B (120min). Solvent A
was 0.1% formic acid in water, whereas B was 0.1% formic
acid in acetonitrile. The injection volume was 2 µL. The
MS equipment has a high collision dissociation cell
(HCD) for fragmentation and an Orbitrap analyzer
(Q-Exactive, Thermo Scientific). A voltage of 3.5 kV was
used for electrospray ionization (Thermo Scientific,
EASY-SPRAY).
XCalibur 3.0.63 software (Thermo Scientific) was used
for data acquisition and equipment configuration that
allows peptide identification simultaneously with their
chromatographic separation. Full-scan mass spectra were
acquired in the Orbitrap analyzer. The scanned mass
range was 400–1800m/z, at a resolution of 70,000 at 400
m/z, and the 12 most intense ions in each cycle were
sequentially isolated, fragmented by HCD, and measured
in the Orbitrap analyzer. Peptides with a charge of +1 or
with unassigned charge state were excluded from frag-
mentation for MS2.
Analysis of MS data
Q-Exactive raw data was processed using Proteome
Discoverer software (version 2.1.1.21, Thermo Scientific)
and was searched against Homo sapiens protein sequence
database with trypsin specificity and a maximum of one
missed cleavage per peptide. Carbamidomethylation of
cysteine residues was set as a fixed modification, and
oxidation of methionine was set as variable modification.
Proteome Discoverer searches were performed with a
precursor mass tolerance of 10 ppm and product ion
tolerance of 0.05 Da. Static modifications were set to
carbamidomethylation of Cys, and dynamic modifications
were set to oxidation of Met and N-terminal acetylation.
Protein hits were filtered for high confidence peptide
matches with a maximum protein and peptide false dis-
covery rate of 1%, which was calculated by employing a
reverse database strategy.
Proteome Discoverer calculates an area for each pro-
tein in each condition. For this process, it uses the area
under the curve of the three most intense peptides for a
protein. The areas were calculated for each of the three
triplicates and were normalized. The data obtained for
the area for each protein were processed via the Perseus
program (Max Planck Institute of Biochemistry, 1.5.5.3
version, available for free) that allows a deeper statistical
analysis. Different scatter plots were prepared according
to the compared samples. For each couple of samples,
we plotted Log p value (−Log Student's T test p value
A_B) on the y-axis versus Student's T test Difference
A_B on the x-axis. Proteins that appear in the volcano
plot with a fold change >2 (<−1 or >1 on the x-axis
of the graph) and a p value below 0.05 (above 1.3 on the
y-axis of the graph) were considered differentially
expressed.
Wound healing assay
Human microvascular endothelial cells (HMEC-1) were
kindly provided by Dr. Gabriela Fernandez from IMEX-
CONICET, Academia Nacional de Medicina. The cells
were seeded to confluency in 12-well culture plates with
MCDB (Molecular, Cellular and Developmental Biology;
Thermo Scientific) medium, 10% fetal bovine serum, 10
ng/ml epidermal growth factor, and 1 µg/ml hydro-
cortisone, and after 18 to 20 h, injuries (wounds) were
La Greca et al. Experimental & Molecular Medicine (2018) 50:119 Page 3 of 12
Official journal of the Korean Society for Biochemistry and Molecular Biology
performed manually using a micropipette tip. Immedi-
ately after this, the cells were washed with PBS, and the
injuries were photographed to register the initial setting
(time zero: 0 h), followed by the addition of α-MEM
medium containing or not containing (without EVs) EVs
collected from PD-MSCs, WJ-MSCs, and iPSCs. After 22
h, the injuries were photographed to mark the conclusion
of the experiment. Images were acquired via EVOS (Life
Technologies) and were analyzed using ImageJ’s MRI
Wound Healing Tool (ImageJ macros, open source soft-
ware – Redmine repository).
Bioinformatic analysis
Quantitation of protein abundance was performed using
the areas calculated by Proteome Discoverer normalized
by the sum of the areas of all the proteins detected in each
run. We further validated this quantitation by comparing
it to their emPAI value35 and performing a Spearman's
correlation analysis (Supplementary Figure 1). Bioinfor-
matic analysis was performed in R. Gene Ontology
Enrichment (Biological Process) using Bioconductor
DOSE36 and cluster.Profiler37 packages and an online
web-based gene analysis toolkit (Cellular Compartments
and node graph)38. Violin plots, heat maps, and principal
component analysis (PCA) were plotted using ggplot2
package. Differential expression analysis was conducted
with the Bioconductor DESeq39 package, using a spectral
count-based quantification (peptide to spectral matching
(PSM))40 as input, and evaluation of the enriched sig-
nature genes was performed with the gene set enrichment
analysis (GSEA) algorithm41, employing 1000 permuta-
tions and default parameters.
Results
Characterization of EVs isolated from cell lines
Although their biogenesis, cargo, and function may
widely differ, EVs remain mainly classified according to
their size. TEM of iPSCs and PD-MSC EVs prepared in
this work revealed vesicles of approximately 107 ± 12 and
101 ± 15 nm, respectively. As Fig. 1a, b show, these
dimensions are compatible with small microvesicle
and exosome sizes. However, the size distribution of PD-
MSC EVs appears to be slightly more homogeneous than
that of iPSC EVs, indicating that the latter might be
composed of more than one type of EVs (Fig. 1b). In
addition, EVs isolated from PSCs (iPSCs or WA09) and
MSCs (derived from pluripotent cells (PDs) or from the
umbilical cord’s WJ) exhibit the exosomal markers CD63,
CD81, and CD9 (Fig. 1c; Supplementary Table 1). Intri-
guingly, pluripotent cells display a considerably lower
intensity of CD9 and CD81 markers; however, the
saturation of anti-CD63 magnetic beads was similar in all
cases (data not shown).
PD-MSC EV protein content exhibits stromal-related
functions
As the number of approved MSC-based therapies rises,
so does concern regarding the source of isolation of these
cells and the scale of culture needed to meet future
demands. Hence, direct differentiation of iPSCs into
MSCs constitutes an interesting alternative source of
MSCs. In this work, we aimed to characterize PD-MSC-
EV proteome and compare it to the proteome of EVs from
the iPSC line from which PD-MSCs were derived in the
first place. Using LC-MS/MS analysis, we determined 629
unique UniProt IDs in iPSC EVs and 560 in PD-MSC EVs.
When compared with each other, only 217 of these pro-
teins were found to be shared (Fig. 2a). Gene Ontology
Enrichment Analysis showed distinct biological processes
for proteins that are either specific for iPSCs (Fig. 2c and
Supplementary Table 2) or PD-MSCs (Fig. 2d and Sup-
plementary Table 3) or are shared by both (Fig. 2b and
Supplementary Table 4). Interestingly, while both types of
EVs share proteins related to immune functions, EVs
secreted by PD-MSCs differ greatly from those secreted
by their isogenic iPSCs. As expected, vesicles from PD-
MSCs mostly reflect stromal functions and extracellular
matrix maintenance, suggesting a role of these EVs over
the mesenchymal niche. Moreover, the unique protein
cargo of iPSC EVs proved to be enriched in more general
cellular processes such as RNA and miRNA catabolism,
translational initiation, or protein targeting to the endo-
plasmic reticulum.
PD-MSC EVs differ from their cell of origin more than
iPSC EVs
A major question regarding exosomal biogenesis is
whether their cargo is selected actively, or in contrast, if it
represents a mere reflection of the cell’s cytoplasm. A
number of laboratories have contributed to unveil the
mechanism of exosomal biogenesis; however, several of
these experiments were conducted in different cell lines,
leading to diverse and sometimes contradictory models.
Taking advantage of the differentiation process to
obtain MSCs from iPSCs, we sought to undertake this
matter by comparing the proteome of each type of EV to
the proteome of the cells that secreted them. Our ratio-
nale is that because PD-MSCs are differentiated directly
from iPSCs, they constitute isogenic yet very different
types of cells; therefore, their EVs might show different
behaviors when compared to their respective cells. Fig-
ure 3 shows the most abundant proteins from iPSCs and
their EVs (1907 and 629 unique UniProt IDs, respectively)
(Fig. 3b), as well as from PD-MSCs and their EVs (1483
and 560 unique UniProt IDs, respectively) (Fig. 3c). The
analysis showed that while iPSC vesicles share 76.63% of
proteins with iPSCs, EVs secreted by PD-MSCs share only
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37.32% of the proteins. In addition, scatter plots of the
abundance of shared proteins show a higher correlation
between iPSC EVs and their cells (Spearman: r= 0.5, p <
2.2e−16) rather than between PD-MSC EVs and their cells
(Spearman: r= 0.12, p < 0.0094), suggesting a closer
identity between the former. Enriched Gene Ontology
analysis of proteins present in the EVs but not in the cell
line that secreted them showed that iPSC EVs are rich in
peptides that regulate proteolytic activity (Fig. 3b, right
panel and Supplementary Table 5), while PD-MSC EVs
appeared to be enriched in immune, extracellular matrix,
and cell adhesion-controlling molecules (Fig. 3c, right
panel and Supplementary Table 6).
EVs segregate together in PCA and Pearson
correlation assay
To explore the idea that PD-MSC EVs differ more with
respect to their original cell than iPSC EVs, we first
compared the abundance of shared proteins between the
iPSC and PD-MSC lines and compared this result to the
abundance of shared proteins between their EVs (Fig. 4a).
Notably, the proteins in common between the cell types
appeared to be detected at similar levels for both, sug-
gesting a similar abundance within the cell (Fig. 4a, left
panel). The same was not observed for EVs. Shared pro-
teins between EVs of both cell types showed a greater
dispersion in abundance, including proteins that were
enriched preferably in iPSC EVs or in PD-MSC EVs; this
indicated that during the differentiation process, packing
of certain proteins may be altered (Fig. 4a, right panel).
Proteins that were overrepresented in iPSC EVs, PD-MSC
EVs, or both are detailed in Supplementary Table 7. The
heatmap analysis, as presented in Fig. 4b, confirmed a
defined cluster of overrepresented proteins for each
group; however, some overlap is appreciated between
groups. Interestingly, unsupervised clustering was per-
formed on the heatmap group together with cellular
datasets on one side and EV datasets on the other. Finally,
Fig. 1 Characterization of EVs isolated from cell lines. a Transmission electron microscopy (TEM) of PD-MSC. b Quantification of diameters of PD-
MSC EVs (left violin plot) and iPSC EVs (right violin plot) using ImageJ. c Flow cytometry analysis of EVs from different cell lines. After isolation, EVs
were bound to anti-CD63-coated magnetic beads and were stained either with a CD81-PE-conjugated or a CD9-APC-conjugated antibody
La Greca et al. Experimental & Molecular Medicine (2018) 50:119 Page 5 of 12
Official journal of the Korean Society for Biochemistry and Molecular Biology
we included in our analysis LC-MS/MS data from EVs
secreted by umbilical cord-MSCs (WJ-MSCs) and the
pluripotent line WA09, which are two related but not
isogenic groups. We performed PCA (Fig. 4c) and plotted
the two principal variables (56.9% of variance explained;
Supplementary Figure 2), which showed certain disper-
sion of variables. However, the EV datasets were again
grouped together, including WA09 EVs and WJ-MSC
EVs. Moreover, the heat map, which showed abundance
of proteins for all EVs, evidenced some degree of overlap
(Supplementary Figure 3). Additionally, iPSC and PD-
MSC cellular datasets showed different components, but
were grouped together and apart from the EV datasets
(Fig. 4d). This finding is again reinforced by the Pearson's
correlation analysis, as displayed in Fig. 4d, where a
positive correlation can be observed between all EV
datasets; however, this correlation is greater among EVs of
the same type (i.e., obtained from pluripotent (iPSCs and
WA09) or multipotent (PD-MSC or WJ-MSC) stem cells;
Supplementary Figure 4).
EV protein content from MSCs reflects regenerative
and immunomodulatory potential
Initial assessment of the MS/MS data showed that the
proteome identified in EVs that were originated from PD-
MSCs and WJ-MSCs is similar (Fig. 4 and Supplementary
Figure 3). Further analysis using a differential expression
of a spectral count-based (PSM37) approach revealed
minor differences between PD-MSC and WJ-MSC EVs,
which evidenced a higher inter-replicate and lower inter-
sample correlation (Fig. 5a). PCA corroborated this
observation (68% of variance explained; Fig. 5b). Although
extensively validated by many authors, the use of spectral
counts for the estimation of differences in peptide abun-
dance was verified in our datasets by studying whether
PSM scores were linearly related to their corresponding
Fig. 2 Comparison between iPSC EVs and PD-MSC EVs. a Venn diagram of UniProt IDs identified by LC-MS/MS. b Enriched Gene Ontology
analysis (Biological Process) of shared UniProt IDs. c Enriched Gene Ontology analysis (Biological Process) of iPSC EV exclusive UniProt IDs. d Enriched
Gene Ontology analysis (Biological Process) of PD-MSC EV exclusive UniProt IDs
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area value (Supplementary Figure 5A). In addition, the
distribution of PSM scores of all peptides contained in
EVs from PD-MSCs, WJ-MSCs, and iPSCs were com-
pared to avoid biased conclusions as a result of substantial
predefined differences in counts between samples (Sup-
plementary Figure 5B). Differential analysis of proteins
contained in EVs from PD-MSCs and WJ-MSCs showed
few proteins that were significantly (p < 0.01) more
abundant in one type of EV with respect to the other
(Supplementary Figure 5C); this result confirmed our
preliminary evidence regarding the identity and quantity
of proteins present in these two types of EVs.
Functional analysis of proteins contained in EVs from
both types of MSCs demonstrates that the majority of
them are part of the cell’s vesicle-mediated secretome
(Supplementary Figure 6A), and their functions relate to
important biological processes such as angiogenesis,
modulation of immune responses, and platelet degranu-
lation (Supplementary Figure 6B). To reinforce our find-
ings, we employed the GSEA41 algorithm to contrast the
two types of MSC-originated EVs to iPSC-originated EVs
(mesenchymal versus pluripotent phenotype) and con-
firmed that the epithelial-to-mesenchymal transition
(EMT) signature genes (Molecular Signatures database
v6.1, GSEA41) are preferentially associated with EVs from
MSCs (Fig. 5c). Coherently, the proteins enriched in this
category correspond to collagen, matrix metalloproteases,
and integrins, among others (Fig. 5d). Furthermore,
Fig. 3 Comparison between EVs and the cells that secreted them. a QuadVenn diagram of UniProt IDs identified by LC-MS/MS. b, Left panel:
Venn diagram of UniProt IDs of iPSCs versus their EVs. Middle panel: scatter plot of relative abundance of shared proteins between iPSCs and their
EVs. Right panel: Enriched Gene Ontology analysis (Biological Process) of iPSC EV exclusive proteins. c, Left panel: Venn diagram of UniProt IDs of PD-
MSCs versus their EVs. Middle panel: scatter plot of relative abundance of shared proteins between PD-MSCs and their EVs. Right panel: Enriched
Gene Ontology analysis (Biological Process) of PD-MSC EV exclusive proteins
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signature gene sets as part of angiogenic, coagulatory, and
complement processes were significantly concordant with
the mesenchymal phenotype as well (Fig. 5e). In contrast,
proteins contained in EVs from iPSCs mainly associated
with cell cycle regulation signature gene sets such as
targets of E2F and MYC transcription factors and G2M
checkpoint regulators (Fig. 5f), advocating a mere reflec-
tion of the ability of pluripotent cells to renew themselves.
Interestingly, EVs from WJ-MSCs evinced potential cell
cycle regulation functions as well. Finally, we performed
in vitro corroboration of our informatic analyses by
exposing HMEC-1 cells to environments enriched with
different EV types obtained from PD-MSCs, WJ-MSCs,
and iPSCs (Fig. 5g). Significant wound closure relative to
time zero (a versus Without EVs: p < 0.05; b
versus Without EVs: p < 0.01) was detected only for
Fig. 4 Clustering and abundance analysis of LC-MS/MS data. a Scatter plot showing abundance of shared proteins of iPSC versus PD-MSCs
(left panel) and iPSC EVs versus PD-MSC EVs (right panel). b Heat map of protein abundance of iPSC and PD-MSC cellular and vesicular proteins.
c Pearson's correlation assay of iPSCs and PD-MSCs and iPSC, PD-MSC, WA09, and WJ-MSC EV proteome. d Principal component analysis (PCA) of the
same groups as in c
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MSC-originated EVs (Fig. 5g and Supplementary Fig-
ure 6C), suggesting that these microvesicles could
potentially regenerate injured endothelial tissue.
Discussion
Mesenchymal stem cells are being increasingly used in
regenerative and immunomodulatory therapies. As the
number of clinical trials and marketed products that
utilize MSC increases, issues regarding the scaling and
validation of cell production will also increase. In parti-
cular, age and condition of donors and a limited expan-
sion span in culture10,11 challenge the academic
community to find new and creative ways to produce
MSCs or mimic their therapeutic properties. In recent
years, different groups have described numerous proto-
cols to obtain MSCs from PSCs12–14. In the past, our
laboratory has focused on conducting this process in an
inexpensive and clinical manner16. A major promise of
MSCs is the use of their exosomes as therapeutic vectors
since cellular therapies have several drawbacks that a
small vesicle such as the exosome does not have. Parti-
cularly, PD-MSC exosomes have already proven to be
effective in ameliorating some pathologies42. However,
literature on characterization of PD-MSC-derived EVs is
scarce. Here, we took advantage of the comparison of PD-
MSC EVs with the EVs secreted by the cells from which
they were derived—the iPSC.
In this work, we showed that EVs secreted from PD-
MSCs and WJ-MSCs are rich in extracellular matrix,
cell–substrate adhesion, and locomotion and cell motility
proteins. Moreover, EVs from PD-MSCs and iPSCs share
cell cycle regulation and DNA replication proteins; how-
ever, intriguingly, these proteins appeared to be better
represented in WJ-MSCs than in PD-MSCs. In contrast,
iPSC EVs appeared to be richer in proteins that regulate
basic cellular functions including RNA and miRNA cat-
abolism and protein trafficking. These findings led us to
believe that while iPSC EVs more resemble the cell
cytoplasm, PD-MSC EVs may have a more stromal-
directed function. EVs play a key role in the modulation of
the immune response against tumors43,44, induction of
angiogenesis45, and cell invasion and metastasis46. In this
sense, the profile of the protein composition of PD-MSC
EVs and their ability to increase the rate of injury repair
explains why they are potential suitable candidates for
tissue regeneration.
To test the hypothesis that iPSCs change the relative
composition of proteins of their EVs when they differ-
entiate to MSCs, we compared EV proteomes to the
ones belonging to their respective cells. We found that,
effectively, iPSC EVs shared a greater proportion of
proteins with iPSCs than PD-MSC EVs do with PD-
MSCs. In addition, when analyzing the relative abundance
of these shared proteins, there appeared to be a better
correlation for iPSCs than for PD-MSCs. In addition,
when correlation or PCA are applied to datasets, EVs
were grouped together, while the cells were consistently
plotted apart. However, the cellular identity of the
EVs was maintained, because iPSCs and WA09 EVs
tended to segregate together on the one hand, while PD-
MSCs and WJ-MSCs tended to be grouped together
on the other. Altogether, these evidence suggest that
iPSC EVs have a cargo that more resembles the cell
cytoplasm than does the cargo from PD-MSC EVs.
Upon differentiation of iPSCs towards MSCs, PD-MSC
EVs may acquire a more specific set of proteins that,
allegedly, have a more specific effect over the stromal
cell niche.
This study focused on the proteomic content of EVs.
However, the vesicular cargo includes mRNA and miRNA
that contribute greatly to their bystander effect. It is
possible that the proteins enclosed in EVs have a more
immediate effect on target cells, while the RNA has a
somewhat retarded influence on cellular behavior. In
addition, the finding that iPSC EVs have a richer content
of proteins that modulate RNA stability contributes to the
idea that there might be some sort of interaction between
proteomic and transcriptomic EV cargo.
It is now known that protein cargo is not randomly
loaded into exosomes. Exosomal proteins are enclosed in
vesicles through ESCRT-dependent and ESCRT-
independent mechanisms27. Moreover, the biogenesis of
exosomes is also controlled by tetraspanins and lipids27,29.
Additionally, the biogenesis and composition of exosomes
seem to be modulated according to the cell type and the
environmental cues, suggesting that different subsets exist
(see figure on previous page)
Fig. 5 Functional analyses of EV content from PD-MSCs and WJ-MSCs. a Correlation analysis of proteins in EVs from PD-MSCs and WJ-MSCs.
Matrix was plotted using three replicates for each EV source. b PCA for samples shown in a. c GSEA profile of EV protein content from PD-MSCs, WJ-
MSCs, and iPSCs against epithelial-to-mesenchymal transition (EMT) signature genes. Proteins originated from both MSC EVs (PD and WJ) were
assigned a mesenchymal phenotype, while proteins from iPSC EVs were assigned a pluripotent phenotype. d Heat map showing relative expression
levels of proteins enriched in EMT GSEA plot (c). Red indicates high abundance, and blue indicates low-to-no abundance. e, f Distribution of
normalized spectral counts expressed as Log 2 in four different sets of signature genes related to regeneration (e) and three related to cell cycle
regulation (f) for EVs originated from PD-MSCs, WJ-MSCs, and iPSCs. g Wound healing assay results expressed as the mean percentage (%) of wound
closure relative to time zero in two independent experiments ± SE. a versus Without EVs (p value <0.05); b versus Without EVs (p value <0.01)
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for these EVs produced within the same cell. Although we
cannot ensure that the proteomic analysis in this work
involves only one type of EV, the homogeneity of sizes
and the presence of CD63, CD9, and CD81 markers
suggest that exosomes are an integral part of isolated EVs.
Despite this, it is possible that differential protein com-
position in iPSC EVs and PD-MSC EVs is explained by
the existence of an entirely distinct set of EVs that are
secreted by one or the other cell type rather than a change
in composition of a particular type of EV. Nevertheless,
we believe that having an isogenic model that presents
changes in its secretome throughout the differentiation
process might be a powerful tool to understand exosome
biology, thus bringing us one step closer to using exo-
somes as a therapeutic vector.
Acknowledgements
This work was funded by the Agencia Nacional de Promoción Científica y
Tecnologica and CONICET (Science National Council) of Argentina. We would
like to thank Dr. Ariel Waisman for his assistance in experimental design and R
programming. This work was supported by the Agencia Nacional de
Promoción Científica y Tecnológica (ANPCyT), the Consejo Nacional de
Investigaciones Científicas y Técnicas (CONICET), and FLENI.
Data availability
LC-MS/MS Raw and Search Engine data files are available for download at Mass
Spectrometry Interactive Virtual Environment (MassIVE): ftp://massive.ucsd.edu/
MSV000081933. Data may also be found under the Proteome Xchange
Consortium under the PXD008669 identifier.
Author details
1LIAN-CONICET, FLENI, Ruta 9 Km 52,5 – (B1625XAF), Belén de Escobar, Buenos
Aires, Argentina. 2Agencia Nacional de Promoción Científica y Tecnolígica
(ANPCyT), Buenos Aires, Argentina. 3Laboratorio de Regulación Génica en
Células Madre, INQUIBICEN – CONICET, Departamento de Química Biológica,
FCEyN, Universidad de Buenos Aires, Buenos Aires, Argentina. 4Consejo
Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires,
Argentina. 5Cátedra de Citología, Histología y Embriología A, Facultad de
Ciencias Médicas, Universidad Nacional de La Plata, Buenos Aires, Argentina
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Supplementary Information accompanies this paper at https://doi.org/
10.1038/s12276-018-0142-x.
Received: 13 January 2018 Revised: 26 April 2018 Accepted: 28 May 2018.
Published online: 10 September 2018
References
1. Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal
stem cells. Science 284, 143–147 (1999).
2. Glennie, S., Soeiro, I., Dyson, P. J., Lam, E. W.-F. & Dazzi, F. Bone marrow
mesenchymal stem cells induce division arrest anergy of activated T cells.
Blood 105, 2821–2827 (2005).
3. Corcione, A. et al. Human mesenchymal stem cells modulate B-cell functions.
Blood 107, 367–372 (2006).
4. Jiang, X.-X. et al. Human mesenchymal stem cells inhibit differentiation and
function of monocyte-derived dendritic cells. Blood 105, 4120–4126 (2005).
5. Bartholomew, A. et al. Mesenchymal stem cells suppress lymphocyte pro-
liferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30,
42–48 (2002).
6. Cantinieaux, D. et al. Conditioned medium from bone marrow-derived
mesenchymal stem cells improves recovery after spinal cord injury in rats: an
original strategy to avoid cell transplantation. PLoS ONE 8, e69515 (2013).
7. Prockop, D. J. Repair of tissues by adult stem/progenitor cells (MSCs): con-
troversies, myths, and changing paradigms. Mol. Ther. 17, 939–946 (2009).
8. Timmers, L. et al. Reduction of myocardial infarct size by human mesenchymal
stem cell conditioned medium. Stem Cell Res. 1, 129–137 (2008).
9. Lai, R. C. et al. Exosome secreted by MSC reduces myocardial ischemia/
reperfusion injury. Stem Cell Res. 4, 214–222 (2010).
10. Lo Surdo, J. & Bauer, S. R. Quantitative approaches to detect donor and
passage differences in adipogenic potential and clonogenicity in human bone
marrow-derived mesenchymal stem cells. Tissue Eng. Part C 18, 877–889
(2012).
11. Stolzing, A., Jones, E., McGonagle, D. & Scutt, A. Age-related changes in human
bone marrow-derived mesenchymal stem cells: consequences for cell thera-
pies. Mech. Ageing Dev. 129, 163–173 (2008).
12. Giuliani, M. et al. Human mesenchymal stem cells derived from induced
pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood 118,
3254–3262 (2011).
13. Trivedi, P. & Hematti, P. Derivation and immunological characterization of
mesenchymal stromal cells from human embryonic stem cells. Exp. Hematol.
36, 350–359 (2008).
14. Wang, X. et al. Human ESC-derived MSCs outperform bone marrow MSCs in
the treatment of an EAE model of multiple sclerosis. Stem Cell Rep. 3, 115–130
(2014).
15. Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent
induced pluripotent stem cells. Nature 448, 313–317 (2007).
16. Luzzani, C. et al. A therapy-grade protocol for differentiation of pluripotent
stem cells into mesenchymal stem cells using platelet lysate as supplement.
Stem Cell Res. Ther. 6, 6 (2015).
17. Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and
friends. J. Cell Biol. 200, 373–383 (2013).
18. Van der Pol, E., Böing, A. N., Harrison, P., Sturk, A. & Nieuwland, R. Classification,
functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 64,
676–705 (2012).
19. Bobrie, A., Colombo, M., Raposo, G. & Théry, C. Exosome secretion: molecular
mechanisms and roles in immune responses. Traffic 12, 1659–1668 (2011).
20. Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular
vesicles. Nat. Rev. Immunol. 14, 195–208 (2014).
21. Xin, H. et al. Systemic administration of exosomes released from mesenchymal
stromal cells promote functional recovery and neurovascular plasticity after
stroke in rats. J. Cereb. Blood Flow Metab. 037506, 1–5 (2013).
22. Giebel, B., Kordelas, L. & Börger, V. Clinical potential of mesenchymal stem/
stromal cell-derived extracellular vesicles. Stem Cell Investig. 4, 84 (2017).
23. Yuan, X. et al. Extracellular vesicles from human-induced pluripotent stem cell-
derived mesenchymal stromal cells (hiPSC-MSCs) protect against renal
ischemia/reperfusion injury via delivering specificity protein (SP1) and
transcriptional activating of sphingosine kinase 1 and inhibiting necroptosis.
Cell Death Dis. 8, 3200 (2017).
24. Chen, B., Li, Q., Zhao, B. & Wang, Y. Stem cell-derived extracellular vesicles as a
novel potential therapeutic tool for tissue repair. Stem Cells Transl. Med. 6,
1753–1758 (2017).
25. Colombo, M., Raposo, G. & Théry, C. Biogenesis, secretion, and intercellular
interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev.
Biol. 30, 255–289 (2014).
26. Stuffers, S., Sem Wegner, C., Stenmark, H. & Brech, A. Multivesicular endosome
biogenesis in the absence of ESCRTs. Traffic 10, 925–937 (2009).
27. van Niel, G. et al. The tetraspanin CD63 regulates ESCRT-independent and
-dependent endosomal sorting during melanogenesis. Dev. Cell 21, 708–721
(2011).
28. Baietti, M. F. et al. Syndecan–syntenin–ALIX regulates the biogenesis of
exosomes. Nat. Cell Biol. 14, 677–685 (2012).
29. Trajkovic, K. et al. Ceramide triggers budding of exosome vesicles into
multivesicular endosomes. Science 319, 1244–1247 (2008).
30. Hurley, J. H. The ESCRT complexes. Crit. Rev. Biochem. Mol. Biol. 45, 463–487
(2010).
La Greca et al. Experimental & Molecular Medicine (2018) 50:119 Page 11 of 12
Official journal of the Korean Society for Biochemistry and Molecular Biology
31. Nabhan, J. F., Hu, R., Oh, R. S., Cohen, S. N. & Lu, Q. Formation and release of
arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at
plasma membrane by recruitment of TSG101 protein. Proc. Natl. Acad. Sci. USA
109, 4146–4151 (2012).
32. Questa, M. et al. Generation of iPSC line iPSC-FH2.1 in hypoxic conditions from
human foreskin fibroblasts. Stem Cell Res. 16, 300–303 (2016).
33. Sommer, C. et al. Induced pluripotent stem cell generation using a single
lentiviral stem cell cassette. Stem Cells 27, 543–549 (2009).
34. Théry, C., Clayton, A., Amigorena, S. & Raposo, G. Isolation and characterization
of exosomes from cell culture supernatants. Curr. Protoc. Cell Biol. 3.22.1–3.22.29
(2006).
35. Ishihama, Y. et al. Exponentially modified protein abundance index (emPAI)
for estimation of absolute protein amount in proteomics by the number of
sequenced peptides per protein. Mol. Cell. Proteom. 4, 1265–1272 (2005).
36. Yu, G., Wang, L.-G., Yan, G.-R. & He, Q.-Y. DOSE: an R/Bioconductor package for
disease ontology semantic and enrichment analysis. Bioinformatics 31,
608–609 (2015).
37. Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for com-
paring biological themes among gene clusters. OMICS J. Integr. Biol. 16,
284–287 (2012).
38. Wang, J., Vasaikar, S., Shi, Z., Greer, M. & Zhang, B. WebGestalt 2017: a more
comprehensive, powerful, flexible and interactive gene set enrichment ana-
lysis toolkit. Nucleic Acids Res. 45, W130–W137 (2017).
39. Anders, S. & Huber, W. Differential expression analysis for sequence count
data. Genome Biol. 11, R106 (2010).
40. Ning, K., Fermin, D. & Nesvizhskii, A. Comparative analysis of different label-free
mass spectrometry based protein abundance estimates and their correlation
with RNA-Seq gene expression data. J. Proteome Res. 11, 2261–2271 (2012).
41. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl. Acad.
Sci. USA 102, 15545–15550 (2005).
42. Zhang, J. et al. Exosomes released from human induced pluripotent stem
cells-derived MSCs facilitate cutaneous wound healing by promoting collagen
synthesis and angiogenesis. J. Transl. Med. 13, 49 (2015).
43. Szajnik, M., Czystowska, M., Szczepanski, M. J., Mandapathil, M. & Whiteside, T. L.
Tumor-derived microvesicles induce, expand and up-regulate biological
activities of human regulatory T cells (Treg). PLoS ONE 5, e11469 (2010).
44. Wieckowski, E. U. et al. Tumor-derived microvesicles promote regulatory
T cell expansion and induce apoptosis in tumor-reactive activated CD8+
T lymphocytes. J. Immunol. 183, 3720–3730 (2009).
45. Grange, C. et al. Microvesicles released from human renal cancer stem
cells stimulate angiogenesis and formation of lung premetastatic niche.
Cancer Res. 71, 5346–5356 (2011).
46. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells
toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891
(2012).
La Greca et al. Experimental & Molecular Medicine (2018) 50:119 Page 12 of 12
Official journal of the Korean Society for Biochemistry and Molecular Biology
